PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod [0.03%]
基于生理的药代动力学(PBPK)模型和临床数据揭示siponimod的消除受CYP3A4和CYP2C9抑制剂的影响减弱
Felix Huth,Kasra Shakeri-Nejad,Anne Gardin et al.
Felix Huth et al.
Multiple sclerosis (MS) is a significant cause of neurological disability in young adults. Siponimod, a potent sphingosine-1-phosphate (S1P) receptor modulator, is used to treat MS by reducing T-cell recirculation and central inflammation. ...
Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants [0.03%]
健康志愿者中新型I型c-Met抑制剂沃利替尼与利福平或伊曲康唑联用的药物相互作用研究
Jingcheng Chen,Jingxuan Wu,Yuqin Song et al.
Jingcheng Chen et al.
Vebreltinib is a novel, highly selective type I c-Met inhibitor developed for treating non-small cell lung cancer (NSCLC) and glioma. As in vitro studies indicate that vebreltinib is primarily metabolized via cytochrome P450 (CYP) 3A4, this...
Clinical Trial
Clinical and translational science. 2026 Jul;19(7):e70648. DOI:10.1111/cts.70648 2026
Correction to "Severe Thiopurine-Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient ith the NUDT15 *1/*6 Genotype: A Brief Report" [0.03%]
NUDT15*1/*6基因型急性淋巴细胞白血病患儿发生严重硫嘌呤类药物所致骨髓抑制的更正通知
Published Erratum
Clinical and translational science. 2026 Jul;19(7):e70652. DOI:10.1111/cts.70652 2026
Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer [0.03%]
基于模型的替雷利珠单抗皮下注射剂型的研发：肿瘤患者中的药代动力学（Ⅰ期）
Xiangyu Liu,Ye Guan,Yixi Liu et al.
Xiangyu Liu et al.
Although tislelizumab is approved across multiple malignancies and dosing schedules, intravenous administration imposes logistical burdens. A subcutaneous formulation may improve convenience and reduce resource demands if comparable exposur...
Clinical Trial
Clinical and translational science. 2026 Jul;19(7):e70649. DOI:10.1111/cts.70649 2026
EPHX2 Orchestrates Intestinal Epithelial Barrier Repair in Ulcerative Colitis: An Integrated Multi-Omics and Experimental Study [0.03%]
整合多组学和实验研究揭示EPHX2在溃疡性结肠炎肠道屏障修复中的作用机制
Tian Dai,Siyu Han,Xiaoping Hu et al.
Tian Dai et al.
Genetic determinants are central to ulcerative colitis (UC) pathogenesis, yet their identification via single-cell transcriptomics and clinical translation remains incomplete. We integrated GWAS-eQTL data with UC-related differentially expr...
A Phase 1, Open-Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Participants [0.03%]
一项在健康受试者中研究鼻用纳洛酮多次给药的药代动力学和安全性的I期、开放标签、随机对照研究
David Cassie,Bob Warnock,Faisal Akhtar et al.
David Cassie et al.
This was a Phase 1, open label, randomized, crossover study to evaluate the safety and pharmacokinetics of multiple doses of intranasal naloxone (NCT05377255). Twenty-four healthy participants were enrolled at a single site in the US to one...
Clinical Trial
Clinical and translational science. 2026 Jul;19(7):e70640. DOI:10.1111/cts.70640 2026
Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real-World Data Screening and in Vitro Validation [0.03%]
苯溴隆作为防治阿尔茨海默病的新型候选药物：来自真实世界数据分析和体外验证的证据
Sho Sakagami,Yuya Yoshida,Shota Uemura et al.
Sho Sakagami et al.
Drug development for Alzheimer's disease (AD) remains challenging, with only a 0.4% success rate from Phase I trials to regulatory approval. Drug repositioning leverages existing approved drugs to identify promising drug alternatives, parti...
Predictive Factors for Relapse in Still's Disease: A Retrospective Cohort Study of Clinical and Laboratory Biomarkers [0.03%]
Still病复发的预测因素：临床和实验室生物标志物的回顾性队列研究
İbrahim Yahya Çakır,Abdulsamet Erden,Yeter Mahmutoğlu et al.
İbrahim Yahya Çakır et al.
This retrospective cohort study aimed to identify clinical and laboratory predictors of relapse in patients with Still's disease. A total of 94 patients diagnosed by Yamaguchi or Fautrel criteria across two rheumatology centers between 2012...
Multicenter Study
Clinical and translational science. 2026 Jun;19(6):e70647. DOI:10.1111/cts.70647 2026
European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives [0.03%]
用于慢性炎症性疾病疗效优化的治疗性抗体欧洲网络：概览、进展和展望
Konstantin Tachkov,Merita Rumano,James Bluett et al.
Konstantin Tachkov et al.
Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over tim...
When Science Outpaces Infrastructure: People, Process, and Technology Challenges for Precision Dosing in Children [0.03%]
当科学超越基础设施时：儿童精准给药的人为、流程和技术挑战
Tamorah Lewis,Karim Jessa,Vijay Ivaturi et al.
Tamorah Lewis et al.
The implementation of novel precision medicine tools in pediatric medicine requires buy-in from multiple interest groups and a shift from traditional medical paradigms. In an effort to implement a precision drug-dosing project for an anti-c...